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Introduction
The neglected tropical diseases (NTDs)
are the most common infections of the
world’s poorest people living in Africa,
Asia, and the Americas [1]. Occurring
predominantly among people who live on
less than US$2 per day or below the
World Bank poverty figure of US$1.25 per
day, the NTDs represent a group of
chronic parasitic and related bacterial
and viral infections that actually promote
poverty because of their impact on child
development, pregnancy outcome, and
worker productivity [2]. The NTDs differ
significantly in their prevalence and dis-
ease burden according to their geographic
and regional presence. Such features for
the NTDs in sub-Saharan Africa [3],
China and East Asia [4], and the Americas
[5–7], respectively, were reviewed previ-
ously. Here, we summarize current knowl-
edge on the prevalence, distribution, and
disease burden of the NTDs in India and
South Asia, focusing on aspects particular
to the region. The review of the literature
was conducted using the online database
PubMed from 2003 to 2010 with the
Medical Subject Headings, the specific
diseases listed in the World Health Orga-
nization’s (WHO) first report on NTDs
[8], and the geographic regions and
countries of South Asia. Reference lists of
identified articles and reviews were also
hand searched as were WHO databases
(http://www.who.int/), including the
WHO’s Weekly Epidemiological Record. Re-
cently, a comprehensive review on the
continuing challenge of infectious diseases
in India was published [9]. However, this
review focuses exclusively on NTDs, many
of which, especially the helminthiases,
were not emphasized previously [9].
Overview of NTDs in India and
South Asia
There is no single and universally
accepted definition of the geographic area
known as South Asia; however, most
definitions include the nations of Bangla-
desh, India, Maldives, Nepal, and Sri
Lanka. The WHO South-East Asian
region also adds DPR Korea, Indonesia,
Myanmar, Thailand, and Timor-Leste
(http://www.searo.who.int/). Because the
prevalence and disease burden of the
major NTDs in East Asia were previously
reviewed and included those five countries
[4], we instead adopted the World Bank’s
use of the term South Asia, which incorpo-
rates the eight nations of Afghanistan,
Bangladesh, Bhutan, India, Maldives,
Nepal, Pakistan, and Sri Lanka [10,11]
(Figure 1). With a few exceptions, very
little data on the NTDs are available from
Afghanistan, so the information provided
here emphasizes the NTDs in the other
seven countries.
Together, the South Asian nations
mentioned above represent a population
of 1.5 billion, or almost one-quarter, of the
global population [11]. The major coun-
tries and their populations are listed in
Table 1, with India accounting for 75% of
the number of people living in South Asia.
Although the World Bank reports that
South Asia has experienced an impressive
economic rebound since the global reces-
sion in 2009, with approximately 7%
overall economic growth in 2010 [11], this
rising tide has left behind a substantial
number of people who remain trapped in
poverty. Today over 1 billion people in
South Asia live on less than US$2 per day
[10,11]. Moreover, the prevalence of un-
derweight children in South Asia exceeds
40% in India, Bangladesh, and Pakistan,
where the rates of malnutrition are consid-
ered among the highest in the world and
are nearly double that of sub-Saharan
Africa [10,11]. As shown in Table 2, the 1
billion or so South Asians living in poverty
suffer from high rates of NTDs. Today,
South Asia accounts for approximately
one-quarter of the world’s soil-transmitted
helminth infections, one-third or more of
the global deaths from rabies, and one-half
or more of the global burden of lymphatic
filariasis,visceralleishmaniasis,andleprosy.
The region is also experiencing an emerg-
ing problem with three major arbovirus
infections, i.e., dengue, Japanese encepha-
litis, and Chikungunya. For several other
important NTDs, such as strongyloidiasis,
toxocariasis, leptospirosis, and amebiasis,
there are no prevalence or disease burden
estimates available.
Helminth Infections
The major helminth infections in South
Asia include three soil-transmitted hel-
minth infections, i.e., ascariasis, trichuria-
sis, and hookworm infection (‘‘hook-
worm’’), and lymphatic filariasis.
Soil-Transmitted Helminth Infections
These helminthiases represent the three
most common NTDs in South Asia.
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TAscariasis (Ascaris lumbricoides infection) is
the most common helminth infection and
NTD in the region, with more than 200
million cases, followed by more than 100
million cases of trichuriasis (Trichuris tri-
chiura) and hookworm, respectively
[12,13]. Whereas Necator americanus ac-
counts for most of the world’s cases of
human hookworm infections, in Uttar
Pradesh and West Bengal States, and
presumably elsewhere in India, mixed
infections with both N. americanus and
Ancylostoma duodenale also occur, as well as
pure A. duodenale infections [14]. A. duode-
nale has also been identified as a cause of
infantile hookworm [15]. In Pakistan,
wastewater used in agriculture was found
to be a significant risk factor for hook-
worm [16]. Overall, South Asia accounts
for approximately one-quarter of the
world’s cases soil-transmitted helminthia-
ses, with the largest number of cases in
India, followed by Bangladesh. These
numbers are based on data published in
2003 [13]; more recent data from the
Global Atlas of Helminth Infections [17]
are not yet available for South Asia.
Because of their pronounced impact on
child growth and development, in 2001
the 54th World Health Assembly estab-
lished a target to reduce the prevalence
and the intensity of soil-transmitted hel-
minth infections in all countries by 50%
and achieve a target of regular deworming
of at least 75% of school-age children at
risk [8]. The major strategy relies on once
or twice yearly mass drug administration
(MDA) using the drug mebendazole or
albendazole as a single dose, with a drug
delivery system relying heavily on schools
and schoolteachers administering the
drugs. Among school-aged children only
Bhutan has achieved this target to date,
although approximately one-half of Sri
Lanka now receives regular deworming in
Figure 1. South Asia. Map created by Priya Chatterjee, The George Washington University, using Arc GIS version 9.3.1.
doi:10.1371/journal.pntd.0001222.g001
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er, a higher percentage of pre-school-aged
children receive deworming, especially in
Bangladesh, India, Nepal, and Sri Lanka,
possibly because children receive single-
dose albendazole as part of lymphatic
filariasis (LF) elimination efforts that
combine MDA with this drug together
with diethylcarbamazine citrate (DEC). In
addition, Nepal has been targeted for
helminth control, together with LF and
trachoma elimination efforts, through a
United States–supported NTD Program
[19], while in Sri Lanka the overall
prevalence of soil-transmitted helminth
infections among school-aged children
falls below the WHO-recommended level
required for annual deworming [20]. A
human hookworm vaccine is also under
development to prevent post-treatment re-
infection [21].
Lymphatic Filariasis (LF)
LF is one of the most debilitating and
disfiguring diseases in South Asia, where
almost all of the cases are caused by
Wuchereria bancrofti [9,22]. The adult
worms inhabit the lymphatics, which in
late stages lead to lymphoedema and
elephantiasis. The disease is poverty-relat-
ed and predominantly affects poor and
marginalized groups [23]. LF-associated
disabilities and deformities result in heavy
economic losses and loss of livelihood [24].
The WHO South-East Asian region
(which also includes the LF-endemic
countries of Indonesia, Myanmar, Thai-
land, and Timor-Leste) accounts for the
single highest disease burden of LF, with
approximately 50% of the estimated 120
million cases globally and 67% of disease
burden when measured in disability-ad-
justed life years (DALYs) [22]. India alone
has 40% of the LF global disease burden
[9]. There is also a huge socioeconomic
impact [2] due to impaired worker
productivity resulting from lymphoedema
of the lower limbs and hydrocele [23,24].
India loses almost US$1 billion annually
from LF [24], while in a recent qualitative
study in Sri Lanka, Perera et al. [23] have
also articulated LF’s social stigma. In
South Asia, the nations of Bangladesh,
India, Maldives, Nepal, and Sri Lanka are
endemic for LF [22].
LF is targeted by WHO for elimination
as a public health problem, defined as a
microfilaraemia rate of ,1%. In 1997, the
World Health Assembly passed a resolu-
tion to work towards LF elimination, and
in 2000 the WHO’s Global Programme to
Eliminate LF established a goal to elimi-
nate the infection by 2020 [8,22]. The
main strategies are: 1) annual MDA with
two drugs, DEC and albendazole, to the
entire eligible population for 5–6 years,
and 2) home-based disability alleviation
and prevention [8,22]. To date, Sri Lanka
has completed and stopped MDA, while
India has implemented MDA with almost
Table 1. The Countries and Population of South Asia and the Percentage Living in
Poverty.
Nation Total Population
a
Percentage of Population Living
Below US$1.25 per Day in 2009
b
India 1.13 billion 41.6%
Pakistan 166 million 22.6%
Bangladesh 160 million 49.6%
Nepal 28 million 55.1%
Afghanistan 28 million Not available
Sri Lanka 20 million 14.0%
Bhutan 0.7 million 26.2%
Maldives 0.3 million Not available
Total South Asia 1.53 billion
aFrom [10,11].
bAsian Development Bank key indicators for Asia and the Pacific.
doi:10.1371/journal.pntd.0001222.t001
Table 2. The Major NTDs in India and South Asia Ranked by Prevalence.
Disease
Number of Cases in India (Percentage
of Global Disease Burden)
Number of Cases in India and South Asia
(Percentage of Global Disease Burden)
Estimated Number of
D A L Y si nS o u t hA s i a
c Reference
Ascariasis 140 million (17%) 237 million (29%)
a 0.4–3.0 million [12,13]
Trichuriasis 73 million (12%) 147 million (24%)
a 0.5–1.5 million [12,13]
Hookworm infection 71 million (12%) 130 million (23%)
a 0.6–5.6 million [12,13]
Lymphatic filariasis ,6 million (5%) (based on 0.53% prevalence) ,60 million (50%)
b 2.9 million
b [22]
Trachoma 1 million (1%–2%) 2 million (2%–4%)
a ,0.1 million [37,38]
Visceral leishmaniasis Not determined 200,000–300,000 cases (40%–60%) 0.4–1.0 million [26,27]
Leprosy 87,190 registered cases (41%) 120,456 registered cases (57%)
b 0.1 million [35]
Rabies 20,000 cases/deaths (36%) $20,000 cases/deaths (.36%) Not determined [8,48]
Japanese encephalitis 1,500–4,000 (incidence) 1,000–3,000 (incidence, Nepal);
100–200 (incidence, Sri Lanka)
0.3 million
b [47,50]
Dengue Not determined Not determined 0.4 million
b [47,50]
Total 5.6–14.8 million
aWorld Bank South Asia Region: Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka.
bWHO South-East Asia Region: Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste.
cDALYs lost from NTDs in South Asia calculated on the basis of the DALYs estimated in references [2,51] multiplied by the percentage of cases in South Asia, with the
exception of the DALYs for dengue and Japanese encephalitis, which were quoted directly from [50].
doi:10.1371/journal.pntd.0001222.t002
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ic areas [22]. India’s National Vector
Borne Disease Programme for LF elimi-
nation is impressive by its sheer scale and
scope [25]. Today, with treatments offered
to the entire endemic population of 600
million people, MDA for LF in India is
that country’s largest national public
health intervention [22]. The overall
prevalence of microfilaremia for LF was
cut in half between 2004 and 2008 and
today the prevalence is 0.53% [22].
Bangladesh, Maldives, and Nepal are also
implementing MDA with high rates of
coverage [22].
Protozoan Infections
Leishmaniasis and amebiasis represent
the highest burden protozoan NTDs.
Visceral Leishmaniasis (VL)
Also known as kala-azar, an estimated
200,000–300,000 people are infected in
South Asia, representing more than 60%
of the world’s cases of VL [26,27]. Many
of South Asia’s VL cases occur in
contiguous areas of Bangladesh, India,
and Nepal [27]; in India VL is found
primarily in the state of Bihar, as well as in
some neighboring districts in Uttar Pra-
desh, and in West Bengal [28]. In South
Asia, VL is caused by Leishmania donovani
and transmitted to humans by the bite of
an infected female sandfly, Phlebotomus
argentipes. VL lowers immunity, causes
persistent fever, pancytopenia, and en-
largement of the spleen and liver, and
leads to very high mortality in untreated
cases. Post kala-azar dermal leishmaniasis
(PKDL) is also an important complication.
In this condition, numerous parasites are
lodged in the lesions in the skin, creating a
chronic source for further transmission.
VL is also an important opportunistic
infection of patients with HIV/AIDS [29].
In South Asia VL is mainly a rural
disease predominantly affecting the poor,
and poverty is a key determinant of this
disease [26,30]. Among the risk factors
that promote survival of the insect vector
and foster disease transmission are mud
walls, dampness in houses, and perido-
mestic vegetation [26]. It has also been
noted that women often delay seeking VL
treatments and are more likely to die from
their infection [30]. Even though VL in
South Asia is anthroponotic (there is no
significant animal reservoir), in some
studies the presence of cattle is associated
with an increased risk of acquiring the
infection [26,30]. VL cases tend to cluster
at the household level and entire villages
can become infected during a VL epidem-
ic over a short period (which is then often
followed by an outbreak of PKDL cases)
[26]. Like many NTDs, VL may actually
promote poverty because of its impact on
children and worker productivity [30]. In
addition, the families of VL patients must
often use a significant percentage of their
earnings or savings for often expensive
treatments. The high cost is a particular
problem in the impoverished state of Bihar
where antimonial drug resistance is high
and the alternative treatments, especially
liposomal amphotericin B, are often pro-
hibitively expensive [26,30].
VL is being targeted by the WHO for
elimination in South Asia [26,27], defined
as an incidence of ,1 case per 10,000
population at each endemic district. The
elimination goal received a boost in 2000
when the ministers of health of Bangla-
desh, India, and Nepal met in Kath-
mandu, Nepal, under the auspices of the
WHO, endorsed a joint action strategy for
this goal, which includes an administrative
commitment to eliminate VL by 2015
[27]. This joint action is essential, based in
part on the finding that 50% of VL cases
occur in the border districts of these three
countries [27]. Following the ministerial
meeting, a draft regional strategic plan was
developed and endorsed by the three
countries during an inter-country meeting
held in Varanasi, India, in November
2003. The plan was reviewed by the
Regional Technical Advisory Group
(RTAG) for kala azar held in India,
December 2004, and was finally adopted
by the national governments and partners
at a meeting in India, in August 2005. The
major elements of the strategy include: 1)
early diagnosis wherever possible, with the
rapid diagnostic test rk-39 and prompt
treatment with the oral drug miltefosine,
injectable paromomycin, or liposomal
amphotericin B [26,27]; 2) integrated
vector management, which includes bed
nets and indoor residual spraying with
DDT and other agents [9,26]; 3) effective
disease surveillance; 4) social mobilization
and partnerships; and 5) clinical and
operational research [27,31]. Among the
challenges to VL elimination in South Asia
are the high rates of PKDL—PKDL
patients represent a potent source for
Leishmania parasites and require a pro-
longed treatment period [26]. Several
candidate vaccines to prevent VL are also
under development [32].
In addition to the problem of VL,
Afghanistan has experienced a re-emer-
gence of disfiguring cutaneous leishmani-
asis (CL), especially in Kabul [8]. Conflict
and its association with a weakened health
care infrastructure combined with envi-
ronmental degradation are key factors
believed to be responsible for this resur-
gence [33].
Amebiasis
Amebiasis is another important proto-
zoan infection, especially in India and
Bangladesh, although there are minimal
surveillance data available and no known
disease burden information. Among the
difficulties in elucidating the extent of this
infection is the absence of widespread
testing to differentiate amebiasis caused by
pathogenic Entamoeba histolytica versus the
non-pathogenic Entamoeba dispar [34].
Neglected Bacterial Infections
The major neglected bacterial infections
in South Asia include leprosy, trachoma,
and leptospirosis.
Leprosy
Caused by Mycobacterium leprae, leprosy is
one of the oldest diseases known to
humankind. The disease primarily affects
skin and peripheral nerves, which can lead
to crippling deformities of the hands, feet,
and face if left undiagnosed or untreated.
The disease disproportionately affects the
poor and other vulnerable and marginal-
ized population groups; its victims are
often exposed to stigma, prejudice, dis-
crimination, and ostracism. With the
implementation of multi-drug therapy
(MDT), a combination of three drugs
promoted by WHO since the early
1980s, there has been a dramatic decline
in global leprosy cases—from .12 million
cases in 1985 to ,0.25 million in 2009
[35]. Encouraged by the success of MDT,
in 1991, the World Health Assembly
passed a resolution to work towards the
elimination of leprosy as a public health
problem, defined as a prevalence of ,1
case per 10,000 population [8]. In 1985,
there were 122 leprosy-endemic countries
with a national prevalence of .1/10,000
population. By the end of 2010, 121 of the
122 countries (Brazil being the only
exception) have achieved the leprosy
elimination goal at the national level and
several of them have also achieved the goal
at the sub-national level. The Global
Leprosy Programme is thus one of the
outstanding success stories in public
health.
Some of the greatest gains in terms of
leprosy elimination have occurred in the
WHO’s South-East Asian region. Among
the key factors that contributed to this
success are: 1) strong political commitment
and allocation of resources by national
governments; 2) a free supply of anti-
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generous grants from the Nippon Foun-
dation and the Novartis Trust for Sustain-
able Development; 3) the leadership pro-
vided by WHO and effective coordination
with national programs and partners; and
4) strong partnerships involving the World
Bank, other United Nations (UN) agen-
cies, international/national nongovern-
mental organizations, and support of key
groups like media, religious leaders, local
community leaders, and youth/women’s
groups. Currently, of the world’s 212,000
registered cases of leprosy, more than one-
half still occur in South Asia [8]. Nepal
was the last country in the region to
achieve the leprosy elimination goal in
2010. India accounts for 40% of the
world’s registered cases and for more than
one-half of the almost 250,000 new leprosy
cases detected annually [35]. The follow-
ing factors have been identified in ensuring
success in leprosy elimination efforts in
South Asia: 1) sustaining political commit-
ment and ensuring adequate resources,
with progress towards further reducing the
burden of leprosy at sub-national levels,
particularly in large countries like Bangla-
desh and India; 2) strengthening integra-
tion of leprosy services into the general
health system through capacity building
and skill development, in order to ensure
and sustain quality leprosy services, in-
cluding diagnosis and treatment at all
levels—this factor has been cited as a key
reason for gains in India’s leprosy elimi-
nation efforts [36]; 3) ensuring a wider
coverage of leprosy services, especially in
currently under-served population groups
such as remote rural areas, urban slums,
and migrant labor; 4) increasing and
sustaining community awareness through
advocacy activities to promote voluntary
case detection and decrease the stigma; 5)
prevention of the care of disabilities and
displacement of leprosy-affected individu-
als and ensuring community-based reha-
bilitation of cured/disabled leprosy per-
sons; and 6) streamlining the MDT supply
and stock management at all levels,
especially in areas of low endemicity.
Active Trachoma
Worldwide, trachoma is a leading cause
of visual impairment and blindness. Ac-
cording to the WHO’s world trachoma
atlas using data from 2003, approximately
1 million cases of trachoma occur in India,
particularly in Rajasthan [37], and
200,000–300,000 cases in Afghanistan,
Nepal, and Pakistan [38]. These cases
represent less than 5% of the world’s
trachoma disease burden [39]. However,
other sources indicate that India may
account for a much larger contribution
to the global trachoma disease burden
[8,37].
Leptospirosis
Although leptospirosis is believed to be
an important NTD in South Asia, there is
a paucity of prevalence and disease burden
information. However, because of its
association with flooding, leptospirosis is
believed to be an important cause of acute
febrile illness in children and aseptic
meningitis, especially in the monsoon
and immediate post-monsoon seasons
[40]. The disease is endemic in the Indian
states of Kerala (where the seroprevalence
is especially high among high-risk groups
such as sewage workers, hospital sanitary
workers, and fisherman), Tamil Nadu, and
the Adamans, and outbreaks are common
in the slums of Mumbai [40].
Neglected Viral Infections
The major neglected viral infections in
India and South Asia include the two
major arboviral infections, dengue and
Japanese encephalitis, and rabies.
Dengue
The first ‘‘virologically proven’’ epidem-
ic of dengue in India occurred in Kolkata
and the Eastern coast in 1963–1964,
subsequently reaching the entire country
with all four dengue serotypes [41].
However, at least a dozen other epidemics
of a dengue-like illness were recorded
throughout the 19th and 20th centuries
[41]. Dengue hemorrhagic fever was first
reported from India only in 1987, with a
large outbreak occurring in Delhi in 1996
[9,41]. Although initially a largely urban
disease, dengue has now spread to rural
areas [41–43], with dengue cases occur-
ring throughout the year [41]. In Bhutan
and Nepal, dengue was first reported in
2004 [44,45]. Overall, in WHO’s South-
East Asia region the number of severe
dengue cases has increased since 2006 [8].
Dengue continues to be reported in all
countries of South Asia and sustained
vector control efforts need to be initiated.
Japanese Encephalitis (JE)
JE is believed to have been introduced
to South Asia from East Asia within the
last half of the 20th century [46]. As a
result of its recent emergence in the
region, JE affects both children and adults
in northern India, Nepal, and Sri Lanka,
whereas it is predominantly a pediatric
disease in the Asia-Pacific region [46].
Large epidemics in northern India and
Nepal occur primarily during the summer
months [47]. Although JE can be a highly
fatal disease, most individuals are asymp-
tomatic. Due to the absence of vaccina-
tion programs and possibly other inter-
ventions, the incidence of JE in
Bangladesh, India, and possibly Pakistan
was noted previously to be on the rise,
whereas it had decreased in Nepal and Sri
Lanka, where both surveillance and
vaccination programs are in place [47].
Today, Bangladesh, India, and Pakistan
exhibit the highest JE disease burden in
South Asia [47]. Two key factors respon-
sible for JE emergence in South Asia
include population growth and irrigated
rice farming, which creates suitable
breeding sites for mosquito vectors [47].
Climate change may also represent an
important factor. In addition to the
vaccination programs in Nepal and Sri
Lanka, the Indian Ministry of Health has
recently developed plans for surveillance
and national vaccination of children;
immunization programs have begun in
both Tamil Nadu and Uttar Pradesh [47].
More than 9 million children were
vaccinated in India in 2006, and since
then vaccination programs have been
introduced into all 62 endemic districts
[9].
Chikungunya
Chikungunya was first identified in
Tanzania in the early 1950s and has
caused periodic outbreaks in Asia and
Africa since the 1960s. It is rarely fatal.
Significant pain occurs in the joints and
the pain can persist for several weeks.
Chikungunya shares some clinical signs
with dengue and can be misdiagnosed in
areas where dengue is common. Between
2001 and 2007, a number of countries
reported Chikungunya outbreaks. In an
outbreak in India in 2006, 1.4 million
cases were reported (although the number
of actual cases is believed to be consider-
ably higher) with Aedes aegypti implicated as
the vector [9].
Rabies
Rabies is an important neglected zoo-
notic disease in South Asia. Canine rabies
is enzootic in India and it is estimated that
India accounts for 36% of the world’s
deaths from rabies (approximately 20,000
or more), with between 30% and 60%
occurring in children, and most of the
cases in rural areas [48]. Almost all of
these deaths are preventable through
prompt medical attention comprised of
wound cleaning and care and post-expo-
sure prophylaxis with rabies vaccine. It is
estimated that the canine population of
India is as high as 25 million [48], which
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vaccination difficult even though it is
considered one of the most cost-effective
ways to reduce human rabies deaths [49].
In 2008, an Indian pilot project to prevent
human rabies deaths was launched by the
National Centre for Disease Control in
five Indian cities. The project includes
programs to increase awareness by the
public and health care professionals about
the importance of immediate medical
attention to animal bites and scratches
[48]. In addition, Sri Lanka has made
great strides in eliminating dog rabies,
while Nepal is producing its own rabies
vaccines for humans and dogs [8].
Throughout the affected enzootic coun-
tries it was recommended that compre-
hensive national rabies control programs
should be established [49].
Concluding Remarks
Together, the NTDs result in an
estimated 5.6–14.8 million DALYs lost
annually (Table 2)—this number exceeds
the DALYs lost annually in the WHO
South-East Asian region as a result of
malaria, while the higher value is approx-
imately the same as the DALYs lost from
HIV/AIDS or tuberculosis [50]. Compre-
hensive programs to eliminate some of the
highest prevalence NTDs are under way
in South Asia. They include activities of
the Global Programme to Eliminate LF,
which is conducting national programs of
MDA, together with an international VL
elimination effort emphasizing the large
number of cases occurring in the border
areas of Bangladesh, India, and Nepal,
and national programs of MDT for
leprosy. Although JE has recently emerged
in South Asia, it may also be controlled or
eliminated through national programs of
comprehensive vaccination.
For other NTDs, national control
programs of preventive chemotherapy,
especially MDA for trachoma (in conjunc-
tion with SAFE strategies) and soil-trans-
mitted helminth infections, and efforts to
vaccinate against canine rabies (as well as
cholera), need to be expanded. Such
programs require integration with im-
provements in sanitation and access to
clean water. Integrated vector manage-
ment that combines bed nets with insec-
ticides are key elements for the control of
VL, CL, and the arbovirus infections.
Among the new control tools under
development that could facilitate NTD
and other disease elimination efforts are
new or improved vaccines under develop-
ment for cholera, dengue, hookworm
infection, leishmaniasis, and malaria [20].
There is an urgent need for better
surveillance and disease burden assess-
ments for most of the NTDs, but especially
for amebiasis, leptospirosis, and the major
arbovirus infections, and for linking MDA,
vaccinations, integrated vector manage-
ment, and improved surveillance together
as part of overall efforts to strengthen
health systems in the region.
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